Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method

References

• He W, Han H, Wang W, Gao B. Anti-influenza virus effect of aqueous extracts from dandelion. Virol J. 2011;8:538-58. doi:10.1186/1743-422X-8-538. PMID: 22168277
   PubMed Web of Science ®Google Scholar
• Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial. Vaccine. 2011;29:7733-39. doi:10.1016/j.vaccine.2011.07.128. PMID: 21835220
   PubMed Web of Science ®Google Scholar
• Dormitzer PR, Tsai TF, Del Giudice G. New technologies for influenza vaccines. Human vaccines & immunotherapeutics. 2012;8(1):45-58. doi:10.4161/hv.8.1.18859
   PubMed Web of Science ®Google Scholar
• Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 2002;15(2):295-323. doi:10.1089/08828240260066242. PMID: 12081014
   PubMed Web of Science ®Google Scholar
• Yang P, Duan Y, Wang C, Xing L, Gao X, Tang C, Luo D, Zhao Z, Jia W, Peng D, et al. Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets. Vaccine. 2011;29(4):698-705. doi:10.1016/j.vaccine.2010.11.026. PMID: 21111782
   PubMed Web of Science ®Google Scholar
• Belshe RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 2004;103:177-85. doi:10.1016/j.virusres.2004.02.031. PMID: 15163507
   PubMed Web of Science ®Google Scholar
• Voeten JT, Kiseleva IV, Glansbeek HL, Basten SM, Drieszen-van der Cruijsen SK, Rudenko LG, van den Bosch H, Heldens JG. Master donor viruses A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 and derived reassortants used in live attenuated influenza vaccine (LAIV) do not display neurovirulent properties in a mouse model. Arch Virol. 2010;155(9):1391-99. doi:10.1007/s00705-010-0719-8. PMID: 20532926
   PubMed Web of Science ®Google Scholar
• Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist®; FluenzTM): A review of its use in the prevention of seasonal influenza in children and adults. Drugs. 2011;71(12):1591-622. doi:10.2165/11206860-000000000-00000. PMID: 21861544
   PubMed Web of Science ®Google Scholar
• Audsley JM, Tannock GA. Cell-based influenza vaccines: Progress to date. Drugs. 2008;68(11):1483-91. doi:10.2165/00003495-200868110-00002. PMID: 18627206
   PubMed Web of Science ®Google Scholar
• Romanova J, Katinger D, Ferko B, Vcelar B, Sereinig S, Kuznetsov O, Stukova M, Erofeeva M, Kiselev O, Katinger H, et al. Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res. 2004;103(1–2):187-93. doi:10.1016/j.virusres.2004.02.032. PMID: 15163508
   PubMed Web of Science ®Google Scholar
• Tang J, Xin L, Guo J, Zhu W, Zhang H, Lang S, Wang D, Shu Y. Preparation and Identification of High Immunogenic A/PR/8/34 Maternal Strain HA Protein for Influenza Virus Classical Reassortment. Bing Du Xue Bao. 2016;32(2):141-4. PMID: 27396155
   PubMedGoogle Scholar
• Engelhardt OG. Many ways to make an influenza virus–review of influenza virus reverse genetics methods. Influenza Other Respir Viruses. 2013;7(3):249-56. doi:10.1111/j.1750-2659.2012.00392.x. PMID: 22712782
   PubMed Web of Science ®Google Scholar
• Nogales A, Martínez-Sobrido L. Reverse Genetics Approaches for the Development of Influenza Vaccines. Int J Mol Sci. 2016;18(1). pii:E20. doi:10.3390/ijms18010020. PMID: 28025504
   PubMed Web of Science ®Google Scholar
• Zhou J, Yang F, Yang J, Ma L, Cun Y, Song S, Liao G. Reassortment of high-yield influenza viruses in vero cells and safety assessment as candidatevaccine strains. Hum Vaccin Immunother. 2017;3(1):111-6. doi:10.1080/21645515.2016.1231261. PMID: 27648636
   PubMed Web of Science ®Google Scholar
• Montagnon BJ. Polio and rabies vaccines produced in continuous cell lines: A reality for Vero cell line. Dev Biol Stand. 1989;70:27-47. PMID: 2759353
   PubMedGoogle Scholar
• Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine. 1998;16(9–10):960-68. doi:10.1016/S0264-410X(97)00301-0. PMID: 9682344
   PubMed Web of Science ®Google Scholar
• Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem. 2008;389(5):569-77. doi:10.1515/BC.2008.060. PMID: 18953724
   PubMed Web of Science ®Google Scholar
• Hu W, Zhang H, Han Q, Li L, Chen Y, Xia N, Chen Z, Shu Y, Xu K, Sun B. A Vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages. Vaccine. 2015;33(2):374-81. doi:10.1016/j.vaccine.2014.11.007. PMID: 25448099
   PubMed Web of Science ®Google Scholar
• Tseng YF, Hu AY, Huang ML, Yeh WZ, Weng TC, Chen YS, Chong P, Lee MS. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: Implications for pandemic preparedness. PLoS One. 2011;6(10):e24057. doi:10.1371/journal.pone.0024057. PMID: 22022351
   PubMed Web of Science ®Google Scholar
• Buonagurio DA, Bechert TM, Yang CF, Shutyak L, D'Arco GA, Kazachkov Y, Wang HP, Rojas EA, O'Neill RE, Spaete RR, et al. Genetic stability of live, cold-adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process. Vaccine. 2006;24(12):2151-60. doi:10.1016/j.vaccine.2005.11.007. PMID: 16413951
   PubMed Web of Science ®Google Scholar
• Zhou F, Zhou J, Ma L, Song S, Zhang X, Li W, Jiang S, Wang Y, Liao G. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1. Biochem Biophys Res Commun. 2012;21(4):850-54. doi:10.1016/j.bbrc.2012.04.101. PMID: 22554519
   PubMed Web of Science ®Google Scholar
• Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938;27:493-97.
   Google Scholar
• WHO. Requirements for influenza vaccine (live). WHO Techn Rep Ser. 1979;638(3):171-92.
   Google Scholar
• Biacchesi S, Skiadopoulos MH, Yang L, Murphy BR, Collins PL, Buchholz UJ. Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression. J Virol Methods. 2005;128(1-2):192-7. doi:10.1016/j.jviromet.2005.05.005. PMID: 15955576
   PubMedGoogle Scholar
• Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol. 1999;73(7):5903-11. PMID: 10364342
   PubMed Web of Science ®Google Scholar